Organigram Global Inc.(OGI)Earnings, Financials & Key Ratios
OGI•NASDAQ
$0.97
Price updated Jul 7, 2026
SectorHealthcareIndustrySpecialty & Generic PharmaSub-IndustryCannabis and cannabinoid product companies
AboutOrganigram Holdings Inc., through its subsidiaries, produces and sells cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including cannabis flowers, cannabis oils, and vaporizers for civilian patients and veterans; adult use recreational cannabis under the Edison Cannabis Co., Trail Blazer, SHRED, SHRED'ems, Big Bag O' Buds, and Monjour brands; and cannabis edibles products and concentrates. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as telephone channels. Organigram Holdings Inc. was founded in 2013 and is headquartered in Moncton, Canada.Show more
- Revenue$186M+16.4%
- EBITDA-$50M-114.1%
- Net Income-$18M+60.9%
- EPS (Diluted)-0.14+70.8%
- Gross Margin3.67%-87.7%
- EBITDA Margin-27.14%-83.9%
- Operating Margin-34.07%-52.7%
- Net Margin-9.55%+66.4%
- ROE-5.43%+65.5%
OGI Price & Volume
Organigram Global Inc. (OGI) stock price & volume — 10-year historical chart
Loading chart...
Persistent Operational Losses Cloud Long-Term Profitability
Investment Thesis • Updated 2026Q2
VerdictNegative: The company's inability to generate positive operating cash flow
Growth:Decelerating
Profitability:Strained
Financial:Healthy
Cash Flow:Burning
Primary Risk:Excise tax margin compression
Key Thesis Takeaways
- Organigram faces significant headwinds as revenue growth contracted by 34.5% in 2026Q2, signaling potential market saturation in the Canadian recreational sector.
- While the company maintains a conservative debt-to-equity ratio of 0.02, the persistent disconnect between net income and operating cash flow, highlighted by a $15.8M cash burn in 2026Q1, suggests a fragile path to self-sustainability.
- Investors should monitor the $52.7M goodwill balance, as future impairment risks remain elevated given the company's inability to achieve consistent operating leverage.
Verdict Logic
evidenced by a $15.8M outflow in 2026Q1 despite reported net income, indicates that the current business model remains fundamentally unproven.
OGI Growth Metrics
Organigram Global Inc. (OGI) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years68.87%
5 Years16.48%
3 Years8.47%
TTM32.58%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-247.88%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-291.87%
Return on Capital
10 Years-14.54%
5 Years-23.29%
3 Years-29.4%
Last Year-16.04%
OGI Recent Earnings
Organigram Global Inc. (OGI) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 2/12 qtrs (17%)●Beat Revenue 2/12 qtrs (17%)
Q2 2026Latest
May 12, 2026Metric
Actual
Est
EPS
$0.01+0.0%
$0.01
Rev
$43M-15.0%
$51M
Q1 2026
Feb 10, 2026Metric
Actual
Est
EPS
$0.02-100.0%
$0.01
Rev
$46M-13.1%
$53M
Q4 2025
Dec 16, 2025Metric
Actual
Est
EPS
$0.20-4058.0%
$0.00
Rev
$57M+13.6%
$51M
Q3 2025
Aug 13, 2025Metric
Actual
Est
EPS
$0.03-200.0%
$0.01
Rev
$52M-28.8%
$73M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 12, 2026 | $0.01vs $0.01+0.0% | $43Mvs $51M-15.0% |
| Q1 2026 | Feb 10, 2026 | $0.02vs $0.01-100.0% | $46Mvs $53M-13.1% |
| Q4 2025 | Dec 16, 2025 | $0.20vs $0.00-4058.0% | $57Mvs $51M+13.6% |
| Q3 2025 | Aug 13, 2025 | $0.03vs $0.01-200.0% | $52Mvs $73M-28.8% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Organigram Global Inc. (OGI)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.97 | $136.23M | -9.82 | 16.42% | -9.55% | -5.43% | — | |
| $0.95 | $365.74M | -1.53 | 5.8% | -91.63% | -38.64% | — | |
| $4.31 | $502.21M | -0.13 | 4.84% | -252.55% | -136.55% | — | |
| $2.67 | $165.39M | -1.77 | -6.37% | -24.14% | -13.4% | — | |
| $2.75 | $1.03B | -112.24 | 64.4% | -0.98% | -0.18% | — | |
| $1.30 | $336.96M | -30.79 | 2.82% | -1.17% | -1% | — |
Compare OGI vs Peers
Organigram Global Inc. (OGI) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when OGI posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
OGI Frequently Asked Questions
Organigram Global Inc. (OGI) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Organigram Global Inc.'s revenue?
Organigram Global Inc. (OGI) reported $257.3M in revenue for fiscal year 2025.
How fast is Organigram Global Inc. growing?
Organigram Global Inc. (OGI) grew revenue by 16.4% over the past year. This is strong growth.
Is OGI profitable?
Organigram Global Inc. (OGI) reported a net loss of $25.0M for fiscal year 2025.
Dividend & Returns
What is OGI's return on equity?
Organigram Global Inc. (OGI) has a return on equity (ROE) of -5.4%. Negative ROE indicates the company is unprofitable.
What is Organigram Global Inc.'s free cash flow?
Organigram Global Inc. (OGI) had negative free cash flow of $19.8M in fiscal year 2025, likely due to heavy capital investments.